Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (45)	4/27/1999 12:35:00 AM
From: Mike McFarland	Respond to of 226

endostatin This one is a few weeks old...hope I did not already post it. Apparently endostatin is tough to produce--that was part of the reason BMS pulled out of the deal with Entremed. MBIO may be a safer play to have some exposure to the Endostatin thing... Anti-Tumor Efficacy Demonstrated With Endostatin Gene Medicine ...delivery of genes to induce the sustained production of biologically active anti-angiogenic factors such as endostatin from muscle tissue may add a novel approach to the arsenal of cancer therapies. biz.yahoo.com Also I have started a new thread for Valentis (MBIO/gmed) Subject 27855